Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica P Anand

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
ACS Chemical Neuroscience|October 12, 2022
Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid OverdoseAlex Disney, Keith M Olson, Amanda M Shafer, et al.
Biopolymers|January 18, 2014
Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesJessica P Anand, Vanessa R Porter-Barrus, Helen V Waldschmidt, et al.
Drug Testing and Analysis|May 17, 2020
In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysisSherif H Hassanien, Jonathon R Bassman, Carmelita M Perrien Naccarato, et al.
Journal of Medicinal Chemistry|November 3, 2015
Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR AffinitiesAubrie A Harland, Larisa Yeomans, Nicholas W Griggs, et al.
Molecules (Basel, Switzerland)|November 30, 2019
Structure-Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid PeptidomimeticsDeanna Montgomery, Jessica P Anand, Mason A Baber, et al.
British Journal of Pharmacology|January 21, 2018
In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administrationJessica P Anand, Kelsey E Kochan, Anthony F Nastase, et al.
ACS Chemical Neuroscience|December 21, 2020
SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine PharmacophoreSean Henry, Jessica P Anand, Ashley C Brinkel, et al.
Journal of Medicinal Chemistry|February 20, 2013
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligandsHenry I Mosberg, Larisa Yeomans, Aubrie A Harland, et al.
Journal of Medicinal Chemistry|January 28, 2020
Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic StabilitySean Henry, Jessica P Anand, Jack J Twarozynski, et al.
Journal of Medicinal Chemistry|May 6, 2016
Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsAubrie A Harland, Aaron M Bender, Nicholas W Griggs, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
ACS Chemical Neuroscience|October 12, 2022
Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid OverdoseAlex Disney, Keith M Olson, Amanda M Shafer, et al.
Biopolymers|January 18, 2014
Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesJessica P Anand, Vanessa R Porter-Barrus, Helen V Waldschmidt, et al.
Drug Testing and Analysis|May 17, 2020
In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysisSherif H Hassanien, Jonathon R Bassman, Carmelita M Perrien Naccarato, et al.
Journal of Medicinal Chemistry|November 3, 2015
Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR AffinitiesAubrie A Harland, Larisa Yeomans, Nicholas W Griggs, et al.
Molecules (Basel, Switzerland)|November 30, 2019
Structure-Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid PeptidomimeticsDeanna Montgomery, Jessica P Anand, Mason A Baber, et al.
British Journal of Pharmacology|January 21, 2018
In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administrationJessica P Anand, Kelsey E Kochan, Anthony F Nastase, et al.
ACS Chemical Neuroscience|December 21, 2020
SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine PharmacophoreSean Henry, Jessica P Anand, Ashley C Brinkel, et al.
Journal of Medicinal Chemistry|February 20, 2013
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligandsHenry I Mosberg, Larisa Yeomans, Aubrie A Harland, et al.
Journal of Medicinal Chemistry|January 28, 2020
Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic StabilitySean Henry, Jessica P Anand, Jack J Twarozynski, et al.
Journal of Medicinal Chemistry|May 6, 2016
Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsAubrie A Harland, Aaron M Bender, Nicholas W Griggs, et al.
Pageof 3